Print Page     Close Window     

SEC Filings

10-K
SERES THERAPEUTICS, INC. filed this Form 10-K on 03/06/2019
Entire Document
 

SERES THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands, except share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Additional

 

 

Other

 

 

 

 

 

 

Stockholders

 

 

 

 

 

 

 

Par

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Equity

 

 

 

Shares

 

 

Value

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

(Deficit)

 

Balance at December 31, 2015

 

 

39,082,017

 

 

 

39

 

 

 

287,937

 

 

 

30

 

 

 

(82,612

)

 

 

205,394

 

Issuance of common stock upon exercise of stock options

 

 

1,273,736

 

 

 

1

 

 

 

2,137

 

 

 

 

 

 

 

 

 

2,138

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

16,857

 

 

 

 

 

 

 

 

 

16,857

 

Unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

(179

)

 

 

 

 

 

(179

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(91,579

)

 

 

(91,579

)

Balance at December 31, 2016

 

 

40,355,753

 

 

 

40

 

 

 

306,931

 

 

 

(149

)

 

 

(174,191

)

 

 

132,631

 

Issuance of common stock upon exercise of stock options

 

 

174,386

 

 

 

 

 

 

116

 

 

 

 

 

 

 

 

 

116

 

Issuance of common stock upon vesting of RSUs, net of tax

   withholdings

 

 

40,876

 

 

 

 

 

 

(33

)

 

 

 

 

 

 

 

 

(33

)

Stock-based compensation expense

 

 

 

 

 

 

 

 

17,362

 

 

 

 

 

 

 

 

 

17,362

 

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

3

 

 

 

 

 

 

3

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(89,380

)

 

 

(89,380

)

Balance at December 31, 2017

 

 

40,571,015

 

 

$

40

 

 

$

324,376

 

 

$

(146

)

 

$

(263,571

)

 

$

60,699

 

Issuance of common stock upon exercise of stock options

 

 

212,240

 

 

 

1

 

 

 

146

 

 

 

 

 

 

 

 

 

147

 

Issuance of common stock upon vesting of RSUs, net of tax

   withholdings

 

 

138,048

 

 

 

 

 

 

61

 

 

 

 

 

 

 

 

 

61

 

Repurchase of common stock for employee tax withholdings

 

 

(17,900

)

 

 

 

 

 

(197

)

 

 

 

 

 

 

 

 

(197

)

Issuance of common stock under ESPP plan

 

 

33,332

 

 

 

 

 

 

257

 

 

 

 

 

 

 

 

 

257

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

16,641

 

 

 

 

 

 

 

 

 

16,641

 

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

146

 

 

 

 

 

 

146

 

Adoption of new revenue standard (ASC 606)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(26,857

)

 

 

(26,857

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(98,942

)

 

 

(98,942

)

Balance at December 31, 2018

 

 

40,936,735

 

 

$

41

 

 

$

341,284

 

 

$

0

 

 

$

(389,370

)

 

$

(48,045

)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

F-5



© Seres Therapeutics. All Rights Reserved.